tetano
Editor, Senior Moderator
Am J Transplant
. 2021 Jun 5.
doi: 10.1111/ajt.16708. Online ahead of print.
T cell-mediated response to SARS-CoV-2 in liver transplant recipients with prior COVID-19
Mario Fernández-Ruiz[SUP] 1 [/SUP], Beatriz Olea[SUP] 2 [/SUP], Patricia Almendro-Vázquez[SUP] 3 [/SUP], Estela Giménez[SUP] 2 [/SUP], Alberto Marcacuzco[SUP] 4 [/SUP], Rafael San Juan[SUP] 1 5 [/SUP], Iago Justo[SUP] 4 [/SUP], Jorge Calvo-Pulido[SUP] 4 [/SUP], Álvaro García-Sesma[SUP] 4 [/SUP], Alejandro Manrique[SUP] 4 [/SUP], Oscar Caso[SUP] 4 [/SUP], Félix Cambra[SUP] 4 [/SUP], Paloma Talayero[SUP] 3 [/SUP], Francisco López-Medrano[SUP] 1 5 [/SUP], María José Remigia[SUP] 6 [/SUP], Tamara Ruiz-Merlo[SUP] 1 [/SUP], Patricia Parra[SUP] 1 [/SUP], Estela Paz-Artal[SUP] 3 [/SUP], Carlos Jiménez[SUP] 4 7 [/SUP], Carmelo Loinaz[SUP] 4 7 [/SUP], David Navarro[SUP] 2 8 [/SUP], Rocío Laguna-Goya[SUP] 3 [/SUP], José María Aguado[SUP] 1 5 [/SUP]
Affiliations
Abstract
Whether immunosuppression impairs severe acute respiratory syndrome coronavirus 2-specific T-cell-mediated immunity (SARS-CoV-2-CMI) after liver transplantation (LT) remains unknown. We included 31 LT recipients in whom SARS-CoV-2-CMI was assessed by intracellular cytokine staining (ICS) and interferon (IFN)-γ FluoroSpot assay after a median of 103 days from COVID-19 diagnosis. Serum SARS-CoV-2 IgG antibodies were measured by ELISA. A control group of non-transplant immunocompetent patients were matched (1:1 ratio) by age and time from diagnosis. Post-transplant SARS-CoV-2-CMI was detected by ICS in 90.3% (28/31) of recipients, with higher proportions for IFN-γ-producing CD4[SUP]+[/SUP] than CD8[SUP]+[/SUP] responses (93.5% versus 83.9%). Positive spike-specific and nucleoprotein-specific responses were found by FluoroSpot in 86.7% (26/30) of recipients each, whereas membrane protein-specific response was present in 83.3% (25/30). An inverse correlation was observed between the number of spike-specific IFN-γ-producing SFUs and time from diagnosis (Spearman's rho: -0.418; P-value = 0.024). Two recipients (6.5%) failed to mount either T-cell-mediated or IgG responses. There were no significant differences between LT recipients and non-transplant patients in the magnitude of responses by FluoroSpot to any of the antigens. Most LT recipients mount detectable -but declining over time- SARS-CoV-2-CMI after a median of 3 months from COVID-19, with no meaningful differences with immunocompetent patients.
. 2021 Jun 5.
doi: 10.1111/ajt.16708. Online ahead of print.
T cell-mediated response to SARS-CoV-2 in liver transplant recipients with prior COVID-19
Mario Fernández-Ruiz[SUP] 1 [/SUP], Beatriz Olea[SUP] 2 [/SUP], Patricia Almendro-Vázquez[SUP] 3 [/SUP], Estela Giménez[SUP] 2 [/SUP], Alberto Marcacuzco[SUP] 4 [/SUP], Rafael San Juan[SUP] 1 5 [/SUP], Iago Justo[SUP] 4 [/SUP], Jorge Calvo-Pulido[SUP] 4 [/SUP], Álvaro García-Sesma[SUP] 4 [/SUP], Alejandro Manrique[SUP] 4 [/SUP], Oscar Caso[SUP] 4 [/SUP], Félix Cambra[SUP] 4 [/SUP], Paloma Talayero[SUP] 3 [/SUP], Francisco López-Medrano[SUP] 1 5 [/SUP], María José Remigia[SUP] 6 [/SUP], Tamara Ruiz-Merlo[SUP] 1 [/SUP], Patricia Parra[SUP] 1 [/SUP], Estela Paz-Artal[SUP] 3 [/SUP], Carlos Jiménez[SUP] 4 7 [/SUP], Carmelo Loinaz[SUP] 4 7 [/SUP], David Navarro[SUP] 2 8 [/SUP], Rocío Laguna-Goya[SUP] 3 [/SUP], José María Aguado[SUP] 1 5 [/SUP]
Affiliations
- PMID: 34092033
- DOI: 10.1111/ajt.16708
Abstract
Whether immunosuppression impairs severe acute respiratory syndrome coronavirus 2-specific T-cell-mediated immunity (SARS-CoV-2-CMI) after liver transplantation (LT) remains unknown. We included 31 LT recipients in whom SARS-CoV-2-CMI was assessed by intracellular cytokine staining (ICS) and interferon (IFN)-γ FluoroSpot assay after a median of 103 days from COVID-19 diagnosis. Serum SARS-CoV-2 IgG antibodies were measured by ELISA. A control group of non-transplant immunocompetent patients were matched (1:1 ratio) by age and time from diagnosis. Post-transplant SARS-CoV-2-CMI was detected by ICS in 90.3% (28/31) of recipients, with higher proportions for IFN-γ-producing CD4[SUP]+[/SUP] than CD8[SUP]+[/SUP] responses (93.5% versus 83.9%). Positive spike-specific and nucleoprotein-specific responses were found by FluoroSpot in 86.7% (26/30) of recipients each, whereas membrane protein-specific response was present in 83.3% (25/30). An inverse correlation was observed between the number of spike-specific IFN-γ-producing SFUs and time from diagnosis (Spearman's rho: -0.418; P-value = 0.024). Two recipients (6.5%) failed to mount either T-cell-mediated or IgG responses. There were no significant differences between LT recipients and non-transplant patients in the magnitude of responses by FluoroSpot to any of the antigens. Most LT recipients mount detectable -but declining over time- SARS-CoV-2-CMI after a median of 3 months from COVID-19, with no meaningful differences with immunocompetent patients.